



Draft Genome Sequence of the Multidrug-Resistant Strain *Pseudomonas aeruginosa* PA291, Isolated from Cystic Fibrosis Sputum

Tiffany Luong,^a Ashley Schumann,^a Douglas Conrad,^b Dwayne Roach^a

^aDepartment of Biology, San Diego State University, San Diego, California, USA ^bDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, California, USA

ABSTRACT Here, we report the genome sequence of PA291, a nonmucoid, multidrugresistant strain of *Pseudomonas aeruginosa* isolated from cystic fibrosis sputum. Short reads were *de novo* assembled into 190 contigs and scaffold assembled to a length of 6.26 Mbp. PhiSpy predicts that PA291 is free of prophages.

P seudomonas aeruginosa causes difficult-to-treat and often multidrug-resistant (MDR) infections, which severely impacts individuals with cystic fibrosis (CF) (1, 2). CF patients are often required to take daily antibiotics, which promotes the development of chronic MDR infections (3). Phage therapy to combat MDR infections is under investigation (4, 5); in part, it requires both phenotypic and genomic characterization of the patient's infectious isolate(s).

In this study, a bacterial colony from CF sputum (under UC San Diego Institutional Review Board-approved protocol number 160078) was cultured overnight on blood agar at 37°C, and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry identified it as belonging to the species *P. aeruginosa*. The strain was named PA291 and found to have a nonmucoid phenotype, and a broth microdilution assay (performed by the UCSD Clinical Molecular Microbiology Laboratory following FDA/CLSI guidelines) revealed strong antibiotic resistance to ceftazidime (MIC > 16 μ g/ml) and intermediate resistance to aztreonam (MIC, 4 μ g/ml), gentamicin (MIC, 8 μ g/ml), and meropenem (MIC, 4 μ g/ml). Moreover, PA291 was lysed by phages PAK_P1, E215, and E217, which are under investigation to treat *P. aeruginosa* infections (5–7).

PA291 DNA extraction and purification was performed after overnight growth in Lennox broth (LB) at 37°C using the phenol-chloroform method (8). The DNA was sent to the Microbial Genome Sequencing Center (Pittsburgh, PA), which prepared an indexed pairedend library using the Illumina Nextera DNA Flex library prep kit and sequenced using the NextSeq 550 sequencer. A total of 4,939,438 reads were obtained, with a mean length of 134 bases. Quality control (QC) of FASTQ files was conducted using fastp v0.21.0 (9), and the short reads were de novo assembled using SPAdes v3.14.1 (10) into 190 contigs. The contigs were assembled using the scaffolder MeDuSa v1.6 (11) with the following reference genomes: PAO1 (GenBank accession number AE004091.2), W16407 (CP008869.2), VA-134 (CP013245.1), DVT779 (CP050330.1), SE5357 (CP054844.1), H47921 (CP008861.1), SE5443 (CP046405.1), PAO1161 (CP032126.1), PABL048 (CP039293.1), and PAC6 (CP053705.1). The quality and metrics were analyzed using QUAST v5.02 (12). All software was used with default settings. PA291 was found to have a length of 6.26 Mbp over 3 contigs and an N_{50} value of 6.16 Mbp. Its GC content is 66.55%. RAST (Rapid Annotation using Subsystems Technology) (13) predicted that PA291 carries 6,114 genes, including motility genes (pulE/tfp, pilB) and alginate biosynthesis genes (alg, kinB) (14). In addition, RAST, RGI v5.1.1, and CARD v3.1.1 (15) were used to identify 47 antibiotic resistance genes, including efflux pumps (MATE family, opr),

Citation Luong T, Schumann A, Conrad D, Roach D. 2021. Draft genome sequence of the multidrug-resistant strain *Pseudomonas aeruginosa* PA291, isolated from cystic fibrosis sputum. Microbiol Resour Announc 10:e00572-21. https://doi.org/10.1128/MRA.00572-21.

Editor David A. Baltrus, University of Arizona

Copyright © 2021 Luong et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Dwayne Roach, dwayne.roach@sdsu.edu.

Received 22 June 2021 Accepted 16 August 2021 Published 9 September 2021 a polymyxin resistance gene (*arnC*), and a fosfomycin resistance gene (*fosA*). PhiSpy v4.2.6 (16) did not predict that PA291 carried complete viral genomes (prophages).

In summary, we report the nearly complete genome sequence of a nonmucoid MDR *P. aeruginosa* strain isolated from CF sputum. The size of PA291 is consistent with that of other *P. aeruginosa* genomes, between 5.5 and 7 Mbp (17). This strain carries several antibiotic resistance, motility, and alginate biosynthesis genes commonly associated with strains isolated from chronic CF infections (18). Extensive antibiotic usage has negative health impacts and further promotes drug resistance. Given the PA291 MDR and lack of prophages, phage therapy may be a suitable alternative treatment.

Data availability. Data for *P. aeruginosa* PA291 can be found in the NCBI database under BioProject accession number PRJNA727612 and BioSample accession number SAMN19026471. The raw reads can be found in the Sequence Read Archive (SRA) under accession number SRR14436913. The RAST annotation of the genome is available on Zenodo (https://zenodo.org/record/5114517#.YPXHVehKguV). The genome sequence of *P. aeruginosa* PA291 was deposited in GenBank under accession number JAGYWJ000000000, where the Prokaryotic Genome Annotation Pipeline (PGAP) annotation is also available.

ACKNOWLEDGMENTS

We thank the Rees-Stealy Research Foundation and ARCS Foundation for funding to T.L. and the UCSD Center for Advanced Laboratory Medicine for conducting the strain identification and antibiogram. We thank Robert Edwards and the SDSU Computational Science Research Center for computational resources.

We declare no competing interests.

REFERENCES

- Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR. 2014. *Pseudomonas aeruginosa in vitro* phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med 190:289–297. https://doi.org/10.1164/ rccm.201404-0681OC.
- Conrad D, Haynes M, Salamon P, Rainey PB, Youle M, Rohwer F. 2013. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol 48:150–156. https://doi.org/10.1165/rcmb.2012-0059PS.
- Mulcahy LR, Isabella VM, Lewis K. 2014. Pseudomonas aeruginosa biofilms in disease. Microb Ecol 68:1–12. https://doi.org/10.1007/s00248-013-0297-x.
- Luong T, Salabarria A-C, Roach DR. 2020. Phage therapy in the resistance era: where do we stand and where are we going? Clin Ther 42:1659–1680. https://doi.org/10.1016/j.clinthera.2020.07.014.
- Forti F, Roach DR, Cafora M, Pasini ME, Horner DS, Fiscarelli EV, Rossitto M, Cariani L, Briani F, Debarbieux L, Ghisotti D. 2018. Design of a broad-range bacteriophage cocktail that reduces *Pseudomonas aeruginosa* biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother 62:e02573-17. https://doi.org/10.1128/AAC.02573-17.
- Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L. 2017. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22:38–47.e4. https://doi.org/10 .1016/j.chom.2017.06.018.
- Luong T, Salabarria A-C, Edwards RA, Roach DR. 2020. Standardized bacteriophage purification for personalized phage therapy. Nat Protoc 15: 2867–2890. https://doi.org/10.1038/s41596-020-0346-0.
- Wilson K. 2001. Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol 56:2.4.1–2.4.5.
- Chen S, Zhou Y, Chen Y, Gu J. 2018. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34:i884–i890. https://doi.org/10.1093/bioinformatics/ bty560.
- Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. 2020. Using SPAdes *de novo* assembler. Curr Protoc Bioinformatics 70:e102.
- Bosi E, Donati B, Galardini M, Brunetti S, Sagot M-F, Lió P, Crescenzi P, Fani R, Fondi M. 2015. MeDuSa: a multi-draft based scaffolder.

Bioinformatics 31:2443–2451. https://doi.org/10.1093/bioinformatics/ btv171.

- Mikheenko A, Prjibelski A, Saveliev V, Antipov D, Gurevich A. 2018. Versatile genome assembly evaluation with QUAST-LG. Bioinformatics 34: i142–i150. https://doi.org/10.1093/bioinformatics/bty266.
- Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, Edwards RA, Gerdes S, Parrello B, Shukla M, Vonstein V, Wattam AR, Xia F, Stevens R. 2014. The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). Nucleic Acids Res 42:D206–D214. https:// doi.org/10.1093/nar/gkt1226.
- Colvin KM, Irie Y, Tart CS, Urbano R, Whitney JC, Ryder C, Howell PL, Wozniak DJ, Parsek MR. 2012. The Pel and Psl polysaccharides provide *Pseudomonas aeruginosa* structural redundancy within the biofilm matrix. Environ Microbiol 14: 1913–1928. https://doi.org/10.1111/j.1462-2920.2011.02657.x.
- 15. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-LV, Cheng AA, Liu S, Min SY, Miroshnichenko A, Tran H-K, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M, Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL, Hsiao WWL, Domselaar GV, McArthur AG. 2020. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res 48:D517–D525. https://doi.org/10.1093/nar/gkz935.
- Akhter S, Aziz RK, Edwards RA. 2012. PhiSpy: a novel algorithm for finding prophages in bacterial genomes that combines similarity- and compositionbased strategies. Nucleic Acids Res 40:e126. https://doi.org/10.1093/nar/gks406.
- Klockgether J, Munder A, Neugebauer J, Davenport CF, Stanke F, Larbig KD, Heeb S, Schöck U, Pohl TM, Wiehlmann L, Tümmler B. 2010. Genome diversity of *Pseudomonas aeruginosa* PAO1 laboratory strains. J Bacteriol 192:1113–1121. https://doi.org/10.1128/JB.01515-09.
- Hoiby N, Jacobsen L, Jorgensen BA, Lykkegaard E, Weeke B. 1974. *Pseudo-monas aeruginosa* infection in cystic fibrosis: occurrence of precipitating antibodies against *Pseudomonas aeruginosa* in relation to the concentration of sixteen serum proteins and the clinical and radiographical status of the lungs. Acta Paediatr Scand 63:843–848. https://doi.org/10.1111/j .1651-2227.1974.tb04874.x.